Made With Uberflip Content Marketing

Investing

Venture capitalists and other investors in biotech discuss the ins and outs of investing.

  • BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities10:02

    BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

    Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and

    Watch Video
  • Testimonials highlight opportunities for China cross-border collaboration2:48

    Testimonials highlight opportunities for China cross-border collaboration

    ChinaBio® Partnering Forum 2017 meets May 31–June 1 in Zhuhai, China. Don’t miss the abundant opportunities to engage with the global life science community and forge valuable cross-border partnership

    Watch Video
  • Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®

    Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®

    The buzz steadily grew as the Health Tech Competition got underway on the last day of BIO-Europe Spring® March 22 in Barcelona. As delegates filed into the competition room, the energy was...

    Read
  • Report findings provide insight into technological innovations and trends in drug development

    Report findings provide insight into technological innovations and trends in drug development

    Knect365 Life Sciences has released a report offering unique insights into the awareness, perceptions and implementation of technological innovations in the drug development industry. Based on a...

    Read
  • BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations5:09

    BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations

    Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 i

    Watch Video
  • BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies8:22

    BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies

    Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical developm

    Watch Video
  • BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech5:47

    BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech

    Antoine Papiernik is the chairman of Paris-based Sofinnova Partners, a venture capital firm that invests in startups and spinout biotech companies primarily in Europe. He spoke with Luke Timmerman, th

    Watch Video
  • Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III

    Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III

    Li Chen, PhD, co-founded Hua Medicine (Shanghai) six years ago with Ge Li, PhD, founder of WuXi AppTec. The company soon in-licensed global rights to a GKA treatment for type 2 diabetes from...

    Read
  • Q1 2017 – Advanced Therapies Make a Strong Showing Early in the Year

    Q1 2017 – Advanced Therapies Make a Strong Showing Early in the Year

    Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence and Nancy Dvorin, Executive Editor, In Vivo Advanced therapy companies started 2017 with a...

    Read
  • BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy8:12

    BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy

    As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's t

    Watch Video
  • BIO Report: Funding cools down after five-year run while early deals stay hot

    BIO Report: Funding cools down after five-year run while early deals stay hot

    Across five metrics for biotech financings tracked by BIO, the sector saw steep drops in 2016 due to uncertainty introduced by political upheavals and regulatory reforms. Yet in each category the...

    Read
  • Biotechs successfully navigate alternative paths to financing

    Biotechs successfully navigate alternative paths to financing

    Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...

    Read
  • Mounting uncertainty threatens research and innovation in medicines

    Mounting uncertainty threatens research and innovation in medicines

    Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...

    Read
  • 2016 – A Year in Review for Advanced Therapies

    2016 – A Year in Review for Advanced Therapies

    Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence | Informa The past year saw intensifying dialogue on how to assess the value of and...

    Read
  • Stirring the Pot for Entrepreneurship in European Tech Transfer

    Stirring the Pot for Entrepreneurship in European Tech Transfer

    Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. The science in many parts of Europe is first-rate. No one disputes...

    Read
  • Increase the value of your asset: Think with the end in mind

    Increase the value of your asset: Think with the end in mind

    Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...

    Read
  • What’s the deal with Immuno-oncology partnering?

    What’s the deal with Immuno-oncology partnering?

    Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...

    Read
  • Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets6:07

    Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

    Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outli

    Watch Video
  • Why the connected patient is the killer app in the digital age of medicine

    Why the connected patient is the killer app in the digital age of medicine

    Guest article by Deb Kilpatrick, PhD, CEO at Evidation Health and Rich Milani, MD, FACC, FAHA, Chief Clinical Transformation Officer at Ochsner Health System If you search on the phrase “killer...

    Read
  • Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were...

    Read
  • loading
    Loading More...